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Abstract
Background: NOTCH1 gene mutations in mantle cell lymphoma (MCL) have been described in about 5–10% of
cases and are associated with significantly shorter survival rates. The present study aimed to investigate the
biological impact of this mutation in MCL and its potential as a therapeutic target.
Methods: Activation of Notch1 signaling upon ligand-stimulation and inhibitory effects of the monoclonal anti-Notch1
antibody OMP-52M51 in NOTCH1-mutated and -unmutated MCL cells were assessed by Western Blot and gene
expression profiling. Effects of OMP-52M51 treatment on tumor cell migration and tumor angiogenesis were evaluated
with chemotaxis and HUVEC tube formation assays. The expression of Delta-like ligand 4 (DLL4) in MCL lymph nodes was
analyzed by immunofluorescence staining and confocal microscopy. A MCL mouse model was used to assess the activity
of OMP-52M51 in vivo.
Results: Notch1 expression can be effectively stimulated in NOTCH1-mutated Mino cells by DLL4, whereas in the
NOTCH1-unmutated cell line JeKo-1, less effect was observed upon any ligand-stimulation. DLL4 was expressed by
histiocytes in both, NOTCH1-mutated and –unmutated MCL lymph nodes. Treatment of NOTCH1-mutated MCL cells with
the monoclonal anti-Notch1 antibody OMP-52M51 effectively prevented DLL4-dependent activation of Notch1 and
suppressed the induction of numerous direct Notch target genes involved in lymphoid biology, lymphomagenesis and
disease progression. Importantly, in lymph nodes from primary MCL cases with NOTCH1/2 mutations, we detected an
upregulation of the same gene sets as observed in DLL4-stimulated Mino cells. Furthermore, DLL4 stimulation of
NOTCH1-mutated Mino cells enhanced tumor cell migration and angiogenesis, which could be abolished by treatment
with OMP-52M51. Importantly, the effects observed were specific for NOTCH1-mutated cells as they did not occur in the
NOTCH1-wt cell line JeKo-1. Finally, we confirmed the potential activity of OMP-52M51 to inhibit DLL4-induced Notch1-
Signaling in vivo in a xenograft mouse model of MCL.
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Conclusion: DLL4 effectively stimulates Notch1 signaling in NOTCH1-mutated MCL and is expressed by the
microenvironment in MCL lymph nodes. Our results indicate that specific inhibition of the Notch1-ligand-receptor
interaction might provide a therapeutic alternative for a subset of MCL patients.
Keywords: Mantle cell lymphoma, Notch1, Delta-like ligand, Angiogenesis, OMP-52M51
Background
Although with current standard therapy high initial re-
sponse rates can be achieved, early relapses and rapid
disease progression determine the clinical course of
most mantle cell lymphoma (MCL) patients [1]. In the
last years, new therapies were approved targeting the
proteasome, the PI3K-Akt-mTOR pathway, the B-cell
receptor (BCR) signaling pathway and the anti-apoptotic
Bcl-2 protein family. Yet, MCL remains an incurable dis-
ease [2]. The t (11;14)(q13;q32) translocation leading to
Cyclin D1 overexpression is the primary oncogenic event
in MCL pathogenesis [3]. Furthermore, constitutive acti-
vation of BCR signaling plays an important role in dis-
ease development [4]. Additionally, genomic profiling
revealed a high number of secondary genetic alterations
and recurrent mutations affecting cell cycle, DNA dam-
age response and apoptosis pathways that contribute to
pathogenesis and aggressiveness of MCL [3]. Among
them, NOTCH1 gene mutations have been described
with a frequency of 5–10% and were shown to be associ-
ated with shorter survival rates [5, 6]. Therefore, further
investigation of the biological effect of this mutation in
MCL and its potential as a therapeutic target is of great
interest.
The majority of the previously described NOTCH1-
mutations in MCL consist of either small frameshift-
causing indels or nonsense mutations in exon 34 [6].
These mutations lead to truncation of the C-terminal
PEST-domain, thereby removing the recognition site
from the ubiquitin ligase degradation complex, resulting
in a more stable and transcriptionally active form of
Notch1-intracellular domain (NICD). The Notch signal-
ing pathway operates in a context- and tissue-dependent
way participating in diverse cellular processes, such as
cancer stem cell biology, angiogenesis, cell proliferation
and survival [7]. In addition to the well-known Notch
target genes HES1 and HEY1, two basic-helix-loop-helix
(Bhlh)-class of transcription factors, numerous genes
have been identified as directly regulated by activated
Notch1 [8]. Some cancer-related target genes of Notch
include NF-κB family members, CYCLIN D1, p21,
GATA3, MYC and DTX1 [9]. In mammals, Notch signal-
ing is usually activated upon interactions with Delta-like
ligands (DLL1, DLL3, DLL4) and Jagged ligands (JAG1,
JAG2), resulting in a series of proteolytic cleavage events
that finally release NICD from its membrane receptor
and lead to its nuclear translocation [7].
Targeting Notch signaling has been studied in various
cancer types and particularly using gamma-secretase in-
hibitors (GSI) in hematological malignancies [6, 10, 11].
However, the clinical applicability of GSI is limited as it
can cause severe diarrhea resulting from simultaneous
inhibition of Notch1 and Notch2 signaling in gut epithe-
lial stem cells [12, 13]. Thus, alternative strategies for
therapeutic targeting of Notch1 are highly warranted.
Recently, antibodies that inhibit signaling of both, wild-
type and mutated Notch1 receptors have been character-
ized [14]. OMP-52M51 (brontictuzumab) is a full length
IgG2 humanized monoclonal antibody that selectively
binds the negative regulatory region of the Notch1 re-
ceptor leading to inhibition of Notch1 signaling [15]. A
phase I study has been conducted in subjects with solid
tumors showing efficacy in cases with Notch1 pathway
activation [16] . In this study, we investigated the role of
the Notch ligands in activating Notch1 signaling in
NOTCH1-mutated and - unmutated MCL cell lines and
evaluated the effects of OMP-52M51 in these cell lines.
Methods
Cell lines and primary MCL cells
MCL cell lines Mino (CRL-3000), JeKo-1 (CRL-3006)
and REC-1 (CRL-3004), were obtained from American
Type Culture Collection (ATCC). To avoid Mycoplasma
contamination, cell lines were routinely tested for Myco-
plasma infection by PCR. The identity of all cell lines
was verified by using GenePrint® kit (Promega, Madison,
WI, USA). MCL cell lines were cultured in RPMI 1640
complemented with 10–20% fetal bovine serum (FBS), 2
mM L-glutamine and 50 μg/mL penicillin/streptomycin
(Life Technologies, Carlsbad, CA, USA) and grown in a
humidified atmosphere at 37 °C with 5% CO2. The mur-
ine bone-marrow derived stromal cell line OP9 (CRL-
2749; ATCC) overexpressing DLL4 (OP9-DLL4) was
generated and grown as described [17, 18]. Primary cells
from MCL patients were isolated and cultured as de-
scribed [19] and conserved within the Hematopathology
collection of our institution registered at the Biobank
from Hospital Clínic-IDIBAPS (R121004–094). The eth-
ical approval for this project including informed patient
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consent was granted following guidelines of the Hospital
Clínic Ethics Committee.
Ligand stimulation and cell treatment
Four micrograms per milliliter of the recombinant
Notch-receptor-ligands DLL1, DLL4, JAG1 and JAG2
(R&D Systems, Minneapolis, MN, USA) were resus-
pended in phosphate buffered saline (PBS) and stored in
culture plates for 4 h at 4 °C to let them attach to the
plates. MCL cells were treated with 25 μg/mL of OMP-
52M51 or human IgG2 (both kindly provided by
Oncomed Pharmaceuticals, Redwood City, CA, USA) and
incubated at 37 °C for 2 h prior to adding them to the
ligand-coated plates for stimulation. For coculture experi-
ments, OP9 cells were plated overnight, and then medium
was replaced by MCL cells (0.5 × 106 cells/mL) previously
treated for 2 h with OMP-52M51. After 24 h of coculture,
MCL cells were collected by carefully rinsing the wells
without disturbing the stroma monolayer and processed
as required.
Protein analysis
Whole-cell protein extracts were obtained using Triton
containing lysis buffer (Tris-HCl pH 7.6 20mmol/L, NaCl
150mmol/L, EDTA 1mmol/L, 1% Triton X-100) supple-
mented with protease and phosphatase inhibitors (10 μg/
mL leupeptin, 10 μg/mL aprotinin, 1mmol/L phenylmetha-
nesulfonyl fluoride, 5mmol/L NaF, 2mmol/L Na3VO4).
Solubilized proteins were quantified by Bradford protein
assay and 50 μg of protein was analyzed by Western Blot-
ting. The following primary antibodies were used: cleaved-
NOTCH1 (Val1744)(D3B8), MEK1/2, phospho-MEK1/2
(Ser217/221)(41G9) (Cell Signaling, Boston, MA, USA),
ERK1 (K-23), phospho-ERK (Thy202/204) (E-4) (Santa
Cruz, Dallas, TX, USA), α-tubulin and β-actin (Sigma Al-
drich, Saint Louis, MI, USA). Chemiluminescence was de-
tected with ECL substrate (Pierce Biotechnology Waltham,
MA, USA) on a mini-LAS4000 Fujifilm device (Fujifilm,
Valhalla, NY, USA). Protein expression was densitometric-
ally quantified using the Image Gauge software (Fujifilm).
Immunohistochemistry and confocal microscopy
Lymph node (LN) biopsies from MCL cases were obtained
from the Hematopathology collection of our institution
registered at the Biobank from Hospital Clínic-IDIBAPS
(R121004–094). Formalin-fixed paraffin-embedded (FFPE)
tissue slides (serial 8 μm sections) were dewaxed and tissue
antigens were retrieved by boiling for 10–15min in sodium
citrate (10mM, pH6.0). Slides were allowed to cool down to
room temperature (RT) and then washed in distilled water
and PBS. Quenching was carried out using 1% H2O2 in
100% methanol (40min, RT) and permeabilization with 0,3%
Triton-X-100 (20min, Sigma-Aldrich) in PBS. Sections were
incubated overnight with anti-human DLL4 (H-70) (Santa
Cruz) and anti-human CD68 (Dako, Glostrup, Germany).
Background staining was determined by incubating with ir-
relevant antibodies. Unspecific fluorescence was quenched
by incubating with avidin/biotin blocking solutions (Vector
Lab, Burlingame, CA, USA). For DLL4 detection, tissue slides
were incubated with anti-rabbit IgG-HRP antibody (Dako).
Signal was amplified using the Cyanine-3 Tyramide Signal
Amplification Kit (TSA; NEL 744, Perkin Elmer, Waltham,
MA). For CD68 detection, a biotinylated anti-mouse IgG
(Vector Lab) was added following incubation with avidin/
biotin complex (Elite Vectastain ABC Complex kit, Vector
Lab). Signal was developed by adding Alexa-488-conjugated
streptavidin. Nuclei were stained with Topro-3 (Invitrogen,
Carlsbad, CA, USA) and mounted with Fluoromount-G
(Southern Biotech., Birmingham, AL, USA). Images were ac-
quired using a LSM510 laser scan confocal microscope
(Zeiss, Oberkochen, Germany) coupled to an Axiovert200
(Zeiss) microscope, using 63x Plan-Neofluar magnification.
Cell cycle assay
A total of 3 × 105 MCL cells were collected after stimula-
tion with DLL4 and incubated with OMP-52M51 for 48
h. Then cells were fixed in ice-cold 70% ethanol while
being gently vortexed, incubated at − 20 °C for 24 h,
washed in PBS and resuspended in 500 μL of staining so-
lution containing 20 μg/mL propidium iodide (Invitro-
gen) and 100 μg/mL RNase A (Thermofisher) in PBS.
Cells were incubated during 30 min at 37 °C and ana-
lysed using BD LSRFortessa 4 L cytometer (Becton Dick-
inson, Franklin Lakes, NJ, USA). Cell cycle analysis was
performed using FlowJo software (Becton Dickinson).
Chemotaxis assay
MCL cells were stimulated with DLL4 and incubated
with OMP-52M51 for 48 h. Transwell culture polycar-
bonate inserts (6.5 mm diameter, 8 μm of pore size)
(Corning, NY, USA) were transferred to wells containing
600 μL of RPMI supplemented with 0.5% BSA with 200
ng/mL of human recombinant CXCL12 (Peprotech). One
hundred microliter of cell suspension (0.5 x 106cells) was
then added into the transwell inserts. Input cell count was
obtained from adding 100 μL of cell suspension to wells
containing 600 μL of 0.5% BSA in RPMI 1640. After 3 h,
100 μL were collected in triplicates from each lower cham-
ber and input well, viable cells were counted on an Attune
cytometer (Thermofisher, Waltham, MA, USA) under
constant flow rate. Migration is represented as the ratio
between migrated cells and total viable input cells.
Human umbilical vein endothelial cells (HUVEC) tube
formation assay
HUVEC, kindly provided by Dr. MC Cid (IDIBAPS),
were cultured as described [20]. Supernatants from MCL
cells (1 × 106 cells/mL) were collected after 48 h of
Silkenstedt et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:446 Page 3 of 15
OMP-52M51 treatment of DLL4-stimulated cells. 24-
well plates were coated with 300 μL of Matrigel (Becton
Dickinson) before 500 μL of HUVEC (0.5 × 105 cells/mL]
and 500 μL of the supernatants were added. After 24 h,
number of branch points was quantified as a measure of
in vitro angiogenesis as the mean of five randomly
chosen fields from each well. Images were taken with a
DM IL LED microscope coupled to a DFC295 camera
(magnification 100x) with Leica Application Suite v 3.7
software (Leica, Wetzlar, Germany).
Gene expression profiling
Total RNA was extracted using the TRIzol method (Life
technologies) according to manufacturer’s instructions.
RNA integrity was examined with the Agilent 2100 Bioa-
nalyzer (Agilent Technologies, Santa Clara, CA, USA)
and only high quality RNA samples were further proc-
essed. RNA from MCL cell lines was hybridized to a
Gene Chip HT HG-U219 array, according to Affymetrix
(Santa Clara, CA, USA) standard protocols. RNA from
MCL lymph nodes was hybridized to a Gene Chip Human
Genome U133 plus 2.0 arrays, according to Affymetrix
standard protocols. Determination of the detection call for
each probe set of the array was obtained with GeneChip®
Command Console® Software (AGCC) (Affymetrix). Raw
data was normalized using the Robust Multichip Analysis
(RMA) algorithm of the BioConductor Affy Package. Differ-
ential expression data analysis was carried out using the
Multiexperiment Viewer Platform (TM4-MEV) [21]. The
number of statistically significant up- and down-regulated
genes was determined using Rank Products methodology
[22] for cell lines, and Volcano plot [23] for MCL lymph
nodes, both setting up a false discovery rate (FDR) < 0.2 and
an absolute fold change (FC) > 1.75. PANTHER (http://
pantherdb.org/) was used to perform gene ontology (GO)
pathways analysis [24] to visualize the relationships between
the significantly modulated genes of NOTCH-mutated MCL
lymph nodes and proteins in known pathways of biological
processes [25]. Primary microarray data of MCL cell lines
and primary MCL lymph nodes are available at the Gene
Expression Omnibus (GEO) of the National Center for Bio-
technology Information under accession Nos. GSE125349,
GSE36000 and GSE46969.
Gene set enrichment analysis (GSEA)
For GSEA, the desktop application version 2.0 (GSEA,
Broad Institute at MIT, Cambridge, MA; http://www.
broadinstitute.org/gsea/) was applied using experimen-
tally derived custom genes. The “Custom MCL” gene set
was designed by manually grouping gene sets involved
in pathways of Notch-activated genes in MCL according
to the results described by Ryan et al. [26]. Briefly, we
searched molecular signatures (http://software.broadin-
stitute.org/gsea/msigdb/) corresponding to the pathways
described in the GO canonical pathways analysis and
GSEA analysis of transcripts increased by Notch in Mino
cells (except MYC), and the significant genes were
grouped into specific pathways (Additional file 1: Table
S1). The “NOTCH1 direct targets” gene set was also
constructed based on the 79 genes described by Ryan
et al. [26]. Similarly, the “NOTCH1 custom” gene set
was designed by manually selecting significant Notch1
related genes found in the literature [6, 11, 15, 27–30].
Two-class analysis with 1000 permutations of gene sets
and a weighted metric was used for all cases. The resulting
gene sets with a false discovery rate (FDR) < 0.05 were
considered to be significant, except for the “NOTCH1”
gene set, where a FDR < 0.12 was used. GSEA analysis was
performed of MCL cell lines stimulated or not with DLL4
and treated or not with OMP-52M51 and of MCL lymph
node tissues with or without mutations in a NOTCH gene.
HeatMaps were created using the Morpheus software
(https://software.broadinstitute.org/morpheus/) followed
by hierarchical clustering using one minus Pearson correl-
ation of the average of gene expression in order to illus-
trate the differential expression of those genes significantly
modulated by DLL4 stimulation and OMP-52M51 treat-
ment in the MCL cell lines and by NOTCH gene mutation
in MCL lymph node tissues for the all custom gene sets
analysis performed.
In vivo mouse model
NSG (NOD-scid-gamma) mice were injected intraven-
ously (i.v.) with 10 × 106 Mino cells. MCL cell engraftment
was periodically monitored over a 3months period. After
3months, mice presented infiltration in several organs.
Tumor cells from lymph nodes were collected, cultured in
RPMI 1640 + 10% FBS as described above and cryopre-
served after several passages. We next confirmed that
these Mino cells engraft faster in a secondary transplant
(45–60 days). Again, these cells obtained from lymph
nodes were collected and cryopreserved. These “fast
engrafting” tumor cells were then thawed and expanded
to get enough cells for in vivo studies. 225 × 106 Mino
cells were then stimulated ex vivo by coculturing them
with OP9-DLL4 cells (7.5 × 106 Mino cells/plate 100 × 20
mm2 (Corning). After 24 h of incubation, 15 × 106 stimu-
lated Mino cells were injected into the intraperitoneal cav-
ity (IC) of 12 female NSG mice at the age of 10 weeks.
Mice were treated intraperitoneally 1 day prior to injec-
tion of cells and then every 4 days with 20mg/kg of OMP-
52M51 or control antibody human IgG2 (6 mice/group).
After 10 days, mice were sacrificed and a peritoneal lavage
(PL) was done by injecting the cavity with 5mL of cold
PBS. Human B-cells were purified by using human CD19
beads. Protein extracts were obtained and expression of
cleaved Notch1 was analyzed by Western Blot. Procedures
involving animals and their care are conforming to
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institutional guidelines that comply with national and
international laws and policies (EEC Council Directive 86/
609, OJ L 358, 12 December, 1987) and were authorized
by the local ethical committee.
Statistical analysis
Data is represented as the mean ± SD of 3 independent ex-
periments. All statistical analyses were done by using
GraphPad Prism 6.01 software (GraphPad Software, La
Jolla, CA, USA). Volcano plot of P values as a function of
weighted FC for mRNA was performed by using Multiplot
Studio v1.5.20 software (Benooist-Mathis Lab, Harvard
Medical School, MA, USA). Comparisons between 2 groups
of samples were analyzed with Kruskall-Wallis nonparamet-
ric test followed by Mann-Whitney U test. Results were
considered statistically significant when P < 0.05 (*P < 0.05;
**P < 0.01; ***P < 0.001).
Results
Activation of Notch1 signaling can effectively be achieved
by stimulation with DLL4 in NOTCH1-mutated MCL cells
A NOTCH1-mutation affecting the PEST-domain in
exon 34 (p.Q2487*) was described in the established
Fig. 1 Activation of Notch1 signaling can effectively be achieved by stimulation with DLL4 in NOTCH1-mutated MCL cells. a Mino, REC-1 and
JeKo-1 cells were stimulated with the different soluble ligands JAG1, JAG2, DLL1 and DLL4 (10 μg/mL). Protein expression levels of cleaved
Notch1 were determined by Western Blot analysis after 48 h (n = 3, one representative experiment is shown). b Mino cells were cocultured with
mesenchymal stem cells expressing DLL4 (OP9-DLL4) or GFP-transfected control cells for 48 h and protein expression of cleaved Notch1 was
analyzed by Western Blot. [(n=3, one representative experiment is shown). c Double staining of MCL lymph node (LN) with anti-CD68 (marker of
histiocytes, green) and anti-DLL4 (red). Nuclei were stained with Topro-3 (blue). Images were acquired using a LSM510 laser scan confocal
microscope coupled to an Axiovert 200 microscope, using 63x Plan-Neofluar magnification. Images from a representative case per group
are shown
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MCL cell line Mino [5, 6]. The effect of this mutation is
considered to be ligand-dependent. In contrast, the
MCL cell line REC-1 presented an intragenic deletion in
exon 28 encoding for a truncated Notch1 protein with in-
creased activity in a ligand-independent fashion [26, 31].
First, we analyzed which Notch ligand was the most ef-
fective to stimulate Notch1 signaling in MCL. NOTCH1-
mutated cell lines Mino and REC-1 and the NOTCH1-wt
cell line JeKo-1 were stimulated with the recombinant li-
gands DLL1, DLL4, JAG1 and JAG2 and the Notch activa-
tion status in these samples was determined by Western
Blot analysis of cleaved Notch1. As shown in Fig. 1a,
DLL4 and DLL1 activated the expression of cleaved
Notch1 in Mino cells, DLL4 being the most potent ligand.
In contrast, these ligands induced only a minor Notch1
activation in unmutated JeKo-1 cells. We confirmed that
REC-1 cells overexpressed cleaved Notch1 independently
of the ligands. The effect of DLL4 was then confirmed by
coculturing of Mino cells with the bone-marrow derived
mesenchymal stem cell line OP9 overexpressing DLL4
(OP9-DLL4), which represents a cell culture model better
reflecting the situation in vivo, where Notch1 ligands are
usually presented by microenvironmental cells [26, 31].
Increased expression of cleaved Notch1 in Mino cells
upon coculture with OP9-DLL4 cells was detected by
Western Blot (Fig. 1b). In view of the remarkable in vitro
effect of DLL4 in NOTCH1-mutated MCL, we sought to
characterize which cells could express this ligand and trig-
ger Notch activation in vivo. We therefore analyzed the
expression of DLL4 in MCL lymph nodes (LN) using im-
munofluorescence staining and confocal microscopy. We
found that DLL4 was widely expressed in the vascular
endothelium (data not shown) and, importantly, it was
expressed by some histiocytic (CD68+) cells in both
NOTCH1-mutated and -unmutated cases (Fig. 1c).
Treatment of NOTCH1-mutated MCL cells with OMP-
52M51 effectively prevents DLL4-dependent activation of
Notch1
We next investigated the effect of the humanized mono-
clonal Notch1 antibody OMP-52M51 in NOTCH1-mu-
tated (Mino) and unmutated (JeKo-1) MCL cell lines.
Since the recognition-binding site of OMP-52M51 in the
EGF-like domain is missing in the REC-1 cell line due a
deletion in this site [26], this cell line was not suitable
for further investigation.
We observed that treatment of DLL4-stimulated Mino
cells with OMP-52M51 for 24 and 48 h resulted in in-
hibition of DLL4-mediated cleaved-Notch1 overexpres-
sion. This effect could also be observed in primary cells
from a NOTCH1-mutated MCL case [MCL#1] carrying
the typical 2-bp deletion in exon 34 (c.7541_7542delCT)
(Fig. 2a). We confirmed the potential of OMP-52M51 to
inhibit DLL-stimulated induction of Notch1 signaling
also in the coculture system of Mino cells with OP9-
DLL4 (Fig. 2b). Again, no effect was detected in the
NOTCH1-wt JeKo-1 cell line.
To evaluate the effect of OMP-52M51 on downstream
signaling of Notch1, we performed a gene expression
profile analysis in JeKo-1 and Mino cells stimulated with
DLL4 and treated with OMP-52M51 for 48 h. Using the
GSEA software analyzing a customized NOTCH1 set of
genes (NOTCH1 custom) [6, 11, 15, 27–30], we detected
44 significantly upregulated leading edge genes (Fig. 2c,
Additional file 2: Table S2) upon DLL4-treatment in
Mino cells (FDR < 0,123; p < 0,005, NES > 1.48). As dis-
played in the Z score heatmap, the significantly modu-
lated genes upon DLL4 stimulation in Mino cells were
effectively downregulated by treatment with OMP-
52M51 (Fig. 2c).
When we applied a signature of NOTCH1 target genes
described in MCL cells (NOTCH1 direct targets) [26], a
strong upregulation of these genes was detected in Mino
cells stimulated with DLL4 (FDR < 0.001; p < 0.001,
NES = 3.00). A good correlation was also observed in
JeKo-1 stimulated with DLL4 (FDR = 0.025; p = 0.025,
NES = 1.40) (Additional file 3: Table S3 and Figure S1),
confirming again that in NOTCH1-unmutated cells the
activation of Notch signaling is less potent than in mu-
tated cells. This may be due to the fact that the signaling
would not be sustained enough as the wild type Notch1
protein has a rapid turnover [7]. Again, OMP-52M51
was able to revert the expression of these direct Notch-
target genes in Mino cells (Fig. 2d).
OMP-52M51 significantly impedes DLL4-induced
upregulation of genes involved in lymphoid biology,
lymphomagenesis and disease progression
Our gene expression results were analyzed by GSEA using
a custom gene set (Custom MCL) generated with data ob-
tained from an integrative analysis of Notch-regulated
transcripts, genomic binding of Notch transcription com-
plexes and genome conformation data in MCL cell lines
[26]. We observed that DLL4 upregulated genes related to
angiogenesis, apoptosis, migration and adhesion, cell cycle,
cytokine signaling, DNA damage and repair, MTOR and
MAPK signaling, leukocyte proliferation and defense re-
sponse (Fig. 3a). OMP-52M51 was able to modulate all
these gene sets only in the NOTCH1-mutated Mino cell
line (Additional file 4: Table S4).
Next, we analyzed the gene expression profile of
lymph nodes from primary MCL cases (n = 21), 3 of
them harboring NOTCH1/2 mutations. By using the
same GSEA analysis, in lymph nodes from primary MCL
cases with NOTCH1/2 mutations, we detected an upreg-
ulation of the same gene sets as observed in DLL4-
stimulated Mino cells (Fig. 3b, Additional file 5: Table
S5). In these cases, to maintain Notch signaling, a
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Fig. 2 Treatment of NOTCH1-mutated MCL cells with OMP-52M51 effectively prevents DLL4-dependent activation of Notch1. a Mino and JeKo-1
MCL cells and NOTCH1-mutated primary MCL cells (patient sample MCL) were treated with OMP-52M51 or IgG2 control antibody and stimulated
with human recombinant DLL4 (4 μg/mL). Protein expression of cleaved Notch1 was determined by Western Blot analysis after 24 and 48 h. b
Mino and JeKo-1 MCL cells were treated with OMP-52M51 and cocultured with DLL4-overexpressing OP9-stromal cells or GFP-transfected control
cells. After 48 h, Western Blot analysis of cleaved Notch1 protein expression was performed. c Significantly modulated genes (FDR < 0.123; p <
0.005; NES > 1.48) related to the Notch1 signaling pathway (NOTCH custom) upon stimulation of Mino and JeKo-1 cells with DLL4 after 48 h
obtained with the Gene Set Enrichment Analysis (GSEA) software. d Significantly upregulated genes (FDR < 0.001; p < 0.001, NES = 3.00) upon
stimulation of Mino and JeKo-1 cells with DLL4 after 48 h obtained with GSEA applying a signature of Notch target genes described in MCL cells
(NOTCH direct targets). Heatmaps were hierarchical clustered by one minus Pearson correlation of the average of gene expression
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Fig. 3 OMP-52M51 significantly impedes DLL4-induced upregulation of numerous genes involved in lymphoid biology, lymphomagenesis and
disease progression mimicking the signature of NOTCH mutated MCL lymph nodes. Heatmaps displaying the significantly upregulated genes and
grouped by pathway signaling obtained after GSEA analysis (Custom MCL set of genes) of (a) Mino cells treated with OMP-52M51 after DLL4-
stimulation and (b) MCL lymph nodes with or without mutation in NOTCH genes. c Volcano plot filtering of 55 genes differentially expressed in
NOTCH-mutated MCL lymph nodes. d Enrichment of biological processes found by PANTHER gene ontology analysis of the volcano-filtered
genes differentially expressed in NOTCH-mutated MCL lymph nodes
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crosstalk between tumor MCL cells and accessory cells,
probably histiocytes, is required. In addition, the PAN-
THER GO analysis of the 55 genes differentially
expressed in MCL lymph nodes carrying NOTCH gene
mutations compared to NOTCH-unmutated MCL lymph
nodes, filtered by Volcano plot (Fig. 3c, Additional file 6:
Table S6), revealed 818 signaling pathways associated
with leukocyte biology primarily enriched for biological
processes associated with disease progression such as
regulation of tethering/rolling, adhesion and migration
of leukocytes (Fig. 3d).
Given that most of these gene sets were related to B
cell activation, regulation of leukocyte tethering or roll-
ing and leukocyte adhesion and migration, we selected
these signatures for further functional validation. As the
activation of ERK is an important integration point for B
cell activation [32], we analyzed phosphorylation of
ERK1/2 and MEK by Western Blot after stimulation of
Mino and JeKo-1 cells with DLL4 and treatment with
OMP-52M51. As displayed in Fig. 4a, DLL4 stimulation
increased phosphorylation of both, MEK and ERK in
Mino cells, indicating that aberrant Notch1 signaling
stimulates B cell activation in MCL. This effect could be
reduced by treatment with OMP-52M51, a process that
was not observed in NOTCH1-unmutated JeKo-1 cells
(Fig. 4a). To corroborate whether the upregulation of
genes related with cell cycle is effectively dependent of
aberrant expression of NOTCH1 genes, we analyzed the
modulation of cell cycle in NOTCH1-mutated Mino cells
and NOTCH1-unmutated JeKo-1 cells treated or not
with DLL4 and/or OMP-52M51. We observed that
DLL4-stimulated Mino cells showed a significant in-
crease of cell proportion in G2-GM phase that was par-
tially reverted (p = 0.057) by incubation with OMP-
52M51 for 48 h (Fig. 4b).
We next studied the effect of aberrant Notch1 signal-
ing on cell migration by means of chemotaxis assays. As
shown in Fig. 4c, DLL4 stimulation of Notch1 signifi-
cantly increased CXCL12-induced migratory capacity of
Mino cells that could be abrogated by treatment with
OMP-52M51. In contrast, no effect could be observed in
unmutated JeKo-1 cells (Fig. 4c).
The DLL4-Notch1 signaling pathway plays an import-
ant role in regulating blood vessel formation during
physiological and pathological angiogenesis [33, 34]. Fur-
thermore, data from our gene expression arrays revealed
that DLL4 stimulation induces several genes related to
angiogenesis. This prompted us to investigate the impact
of activating NOTCH1 mutations on tumor angiogen-
esis. We therefore used supernatants of Mino and JeKo-
1 cells stimulated or not with DLL4 and treated or not
with OMP-52M51 in a tube formation assay with
HUVEC. Supernatants of DLL4 stimulated NOTCH1-
mutated Mino cells significantly increased number of
branch points as a measure of in vitro angiogenesis com-
pared to those of unstimulated cells. Importantly, the
proangiogenic effect of these supernatants could be ef-
fectively abolished by treatment of cells with OMP-
52M51. Again, no differences were detected in unmu-
tated JeKo-1 cells (Fig. 4d).
OMP-52 M51 effectively inhibits DLL4 induced activation
of Notch1 in an in vivo model
Finally, we aimed to confirm the activity of OMP-52M51
in an in vivo MCL model. As NOTCH1-mutated Mino
cells are dependent on ligand activation, these cells were
stimulated ex vivo with OP9-DLL4 cells to ensure hu-
man Notch1 activation. After stimulation of Mino cells
for 24 h, cells were injected into the IC of NSG mice and
treated every 4 days with 20mg/kg of OMP-52M51.
After 10 days, mice were sacrificed and cells were recol-
lected from the IC (Fig. 5a). Total recovery of the periton-
eal cells was evaluated by flow cytometry after staining
with huCD45/CD19/antibodies. This short-term treat-
ment with the anti-Notch1 antibody did not affect cell via-
bility or tumor cell counts (data not shown). Protein
extracts were obtained and Western Blot analysis con-
firmed that OMP-52M51 was able to inhibit cleaved
Notch1 in vivo (Fig. 5b), although this short-term OMP-
52M51 treatment was not enough to cause a significant
efficacy in tumor growth.
Discussion
Activating NOTCH1 mutations are among the most fre-
quent secondary genetic alterations in MCL detected in
5–10% of cases [5, 6, 35]. Similar to CLL, the majority of
NOTCH1 alterations described in MCL are nonsense
truncating mutations and small frame-shift indels lo-
cated in exon 34 which encodes the PEST domain,
resulting in enhanced Notch1 signaling [7, 30]. The clin-
ical significance of this mutation is highlighted by the
fact that patients harboring a NOTCH1-mutation had
significantly shorter overall survival rates [5, 6]. Yet, the
molecular impact of NOTCH1 mutations in MCL is not
well understood. Recently, it has been postulated that
Notch signaling regulates genes involved in BCR and
cytokine signaling as well as the oncogene MYC, which
sustains proliferation of Notch-dependent MCL cell lines
[26]. Targeting Notch signaling has been studied in
various cancer types [6, 10, 36], and particularly in
hematological malignancies carrying NOTCH1 muta-
tions [10, 37]. It has been reported that GSI-mediated
inhibition of Notch signaling in NOTCH1-mutated MCL
cells resulted in reduction of cell proliferation and apop-
tosis induction [6]. However, the clinical applicability of
GSI is limited due to severe gastrointestinal toxicities
[12, 13]. Thus, alternative strategies for targeting Notch
signaling are highly warranted. In this way, we analyzed
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the effect of a humanized IgG2 monoclonal antibody
OMP-52M51 that showed encouraging antitumor effi-
cacy in T-acute lymphoblastic leukemia (ALL) xenograft
models [15]. Recently, phenotypic and molecular fea-
tures of resistance after long-term treatment with OMP-
52M51 have been reported, that are highly
heterogeneous, suggesting that leukemia cells can adopt
several strategies to evade Notch inhibition according to
the therapeutic drug used [38].
In Non-Hodgkin lymphomas, only little is known
about the dependency of Notch1 signaling activation
upon a certain ligand. Candidate cellular sources include
(See figure on previous page.)
Fig. 4 Activating NOTCH1 mutations promote BCR signaling, proliferation, angiogenesis and enhance tumor cell migration upon DLL4-stimulation
that can be abolished by treatment with OMP-52M51. a Effect of DLL4-stimulation and treatment with OMP-52M51 on ERK and MEK
phosphorylation. Mino and JeKo-1 MCL cells were stimulated with DLL4 (4 μg/mL) and treated with OMP-52M51 or IgG2. After 48 h, protein
expression of p-ERK, total ERK1, p-MEK1/2 and total MEK1/2 was assessed by Western Blot [n = 3; one representative experiment is shown]. b
Relative cell proportion in G2-GM phase of cell cycle in Mino and JeKo-1 cells stimulated or not with DLL4 and treated with OMP-52M51 or IgG2
for 48 h. Cell cycle phases were measured by flow cytometry using propidium iodide and analysed using FlowJo software (n = 4, *p = 0.0286, bars
represent the mean ± SD). c Mino and JeKo-1 cells were stimulated with DLL4 and treated with OMP-52M51 or IgG2 for 48 h. Migration of cells
was assessed in a transwell system with inserts of 8 μm pore size. Migration was defined by counting the cells that migrated to the lower
chambers containing medium with the chemoattractant CXCL12 (200 ng/mL) (n = 5, **p = 0.0079, bars represent the mean ± SD). d Cells were
stimulated with DLL4 and treated with OMP-52M51 or IgG2 for 48 h. Supernatants were then harvested and added to HUVEC. After 24 h, the
number of branch points was quantified as the mean of five randomly chosen fields from each well. Pictures were taken with a DM IL LED
microscope coupled to a DFC295 camera (magnification 100x) (n = 5, bars represent the mean ± SD, *p = 0.05; ***p = 0.001). Microscope images
from one representative experiment are shown
Fig. 5 OMP-52M51 effectively inhibits DLL4 induced activation of Notch1 in an in vivo model. a Mino cells were stimulated ex vivo by
coculturing them with DLL4 expressing stromal cells. After stimulation for 24 h, cells were injected into the intraperitoneal cavity of NSG mice.
Mice were treated IP 1 day prior to injection of cells and then every 4 days with 20 mg/kg of OMP-52M51. After 10 days, mice were sacrificed and
cells were recollected from the intraperitoneal cavity. b Expression of cleaved Notch1 was analyzed by Western Blot
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other hematopoietic cells; endothelial cells, which are
capable of inducing Notch signaling in B lymphoma cells
[39] and DLL1/4-expressing fibroblastic cells in second-
ary lymphoid organs [40]. In this study, we show for the
first time that DLL4 is a potent ligand to activate Notch1
signaling in MCL cells harboring a NOTCH1 mutation
in the PEST domain, whereas JAG1 and JAG2 could not
sufficiently stimulate Notch1 activity. DLL4 was shown to
be constitutively expressed in some lymphoid organs,
where it influences regulation of Notch signaling during
hematopoiesis [41]. In T-ALL cells, where mutations in
NOTCH1 are frequent and well characterized, DLL4 plays
an important role as part of the tumor microenvironment
contributing to early steps of T-ALL cell growth [42]. Al-
though immobilized DLL1 was also used to model ligand-
dependent Notch1 activation in MCL [26], the effect of
DLL1 in MCL cells is lower than of DLL4. Only a minor
effect upon any ligand stimulation was observed in
NOTCH1-wt cells corroborating the fact that NOTCH1
mutations in the PEST domain lead to a more stabilized
protein due to loss of the recognition site from the ubiqui-
tin ligase degradation complex [7]. Furthermore, we
provide evidence that DLL4 is expressed in the lymph
node MCL compartment, where it could promote Notch
activation. In particular, we detected DLL4 to be highly
expressed in the vascular endothelium and by some
CD68-positive cells, indicating that DLL4 expressed by
the LN microenvironment might provide a specific niche
for Notch activation.
Furthermore, our results confirm that stimulation of
Notch signaling by Delta-like ligands could have a critical
role in MCL pathogenesis as we observed upregulation of
several direct Notch target genes [26] involved in angio-
genesis, apoptosis, migration and adhesion, cell cycle,
cytokine signaling, DNA damage and repair, MTOR and
MAPK signaling, leukocyte proliferation and defense re-
sponse of B cell activation, cell cycle progression and onco-
genesis both in DLL4-stimulated Mino cells and in lymph
nodes from primary MCL cases carrying NOTCH muta-
tions. In this way, we detected the induction of transcrip-
tion factors genes implicated in B-cell differentiation and
activation, PAX5 and IRF8 [43–46] as well as of MYBL2, a
transcription factor participating in cell cycle progression
[47, 48] and recently described as a direct Notch1 target in
B cell lymphomas [26]. We confirmed a possible inter-
action between Notch and BCR signaling in B cell malig-
nancies [26] as we observed the upregulation of several
genes related to B cell activation (FYN, FGR, NEDD9 and
SH2B2) and an increase of cell proliferation after DLL4
stimulation in NOTCH1-mutated MCL cells. Moreover,
the results obtained for NOTCH -mutated MCL lymph
nodes could be considered a proof-of-concept for those
observed in DLL4-stimulated Mino cells, and are in con-
cordance with the poor overall survival [6] and prognosis
[5] associated with NOTCH mutations in MCL. Our next
aim was to analyze the potential effect of the anti-Notch1
antibody OMP-52M51 on blocking the Delta-like ligand-
induced signal in MCL. Treatment of Mino cells with
OMP-52M51 could effectively inhibit DLL4-dependent
Notch1-activation and suppress transcriptional expression
of several direct Notch target genes described in MCL [26].
These findings are in line with results observed in T-ALL,
where OMP-52M51 treatment of T-ALL patient samples
harboring mutations in the NOTCH1-PEST-domain
caused strong inhibitory effects on the expression of
Notch-target genes [15]. Furthermore, we confirmed that
in our model anti-Notch1 therapy attenuated the expres-
sion levels of the four well known Notch-target genes that
have been described as a marker of the effect of OMP-
52M51 in T-ALL (CR2, DTX1, HES1 and HES4) [15].
Moreover, we elucidated a functional relationship between
Notch1 signaling and microenvironment processes related
to MCL aggressiveness such as cell proliferation, cell mi-
gration and angiogenesis. Notch1 signaling has been shown
to play a role in CCL19-driven homing of CLL cells [49]
and Notch1 signaling inhibition in multiple myeloma was
described to prevent tumor cell migration [50]. Accord-
ingly, we showed that OMP-52M51 reverts the strong in-
duction of gene signatures related to tumor cell migration
and adhesion upon Notch1 activation and prevents DLL4-
stimulated migratory capacity of MCL cells.
The DLL4-Notch1 axis is known to play an important
role in regulating angiogenesis. Previous studies have
shown that productive tumor angiogenesis requires
cooperation between VEGF-A, which induces prolifera-
tion of endothelial ‘tip’ cells and expression of DLL4 in
‘stalk’ cells [51]. In this context, DLL4 inhibits endothe-
lial proliferation and promotes branching morphogen-
esis, and the balance between proliferation and
branching is key to the formation of a functional capil-
lary network. As such, treatment with anti-DLL4 anti-
bodies resulted in disorganized angiogenesis,
characterized by endothelial proliferation without for-
mation of functional capillaries [52]. In line with this,
we showed that supernatants of NOTCH1-mutated
MCL cells stimulated with DLL4 increased HUVEC
tube formation, whereas OMP-52M51 blocked this
proangiogenic effect. We therefore postulate that by pro-
moting pronounced vasculature development, DLL4-
stimulated Notch1 signaling might contribute to the clin-
ically observed aggressive behavior of NOTCH1-mutated
MCL. Interestingly, NRARP, one of the genes with the
strongest induction upon Notch1 stimulation in our gene
expression array, has been described to be related to
Notch signaling [53] and shown to act as a molecular link
between Notch and Wnt signaling in endothelial cells to
control stability of new vessel connections [54]. In this
sense, our results suggest that in MCL, the link between
Silkenstedt et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:446 Page 12 of 15
Notch1 and NRARP might promote angiogenesis and
needs to be further explored.
Importantly, we showed that even if DLL4 could po-
tentially activate Notch1 signaling irrespective of the
mutational status of NOTCH1, its functional effects are
specific for NOTCH1-mutated MCL cells. This might be
due to the fact that in NOTCH1-unmutated MCL, the
weak expression of intracellular cleaved Notch1 upon
ligand-activation seems to be very unstable due to rapid
proteasomal degradation and might not be potent
enough to cause functionally relevant transcriptional ef-
fects. This observation is of clinical relevance as a spe-
cific Notch1-antibody therapy might be a promising
therapeutic alternative for the subgroup of patients with
NOTCH1-PEST-mutations.
Conclusion
We show for the first time that DLL4 is a potent stimu-
lator of Notch1 signaling in NOTCH1-mutated MCL
and that expression of this ligand observed in histiocytic
cells from MCL lymph nodes might provide a specific
niche for Notch activation. We propose a link between
Notch1-induced expression of tumor-promoting genes
and activation of processes contributing to a more
aggressive MCL phenotype. Furthermore, our findings
indicate that specific inhibition of the Notch1-ligand-
receptor interaction provides an efficient and specific
therapeutic alternative for a subset of MCL patients.
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